Intracavitary cisplatin chemotherapy for mesothelioma.
A feasibility study of intracavitary cisplatin was conducted in eight patients with mesothelioma. Cisplatin, 90 mg/m2, was instilled weekly for 3 weeks, followed by a 3-week rest; thiosulfate was given iv to reduce nephrotoxicity. In 50 courses there was no chemical serositis; the major toxic effect was myelosuppression. One patient with measurable disease had a complete response; three others had objective responses.
D000328:Adult; D000368:Aged; D001344:Autopsy; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D005069:Evaluation Studies as Topic; D006801:Humans; D007274:Injections, Intraperitoneal; D007813:Laparotomy; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000139:chemically induced; D009325:Nausea / Q000139:chemically induced; D010997:Pleural Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013909:Thorax
D002945:Cisplatin